Loading...
Market
Biogen completes HI-Bio acquisition by year-end?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Biogen official press release or SEC filings
Story
Biogen (Nasdaq: $BIIB) to Acquire HI-Bio for $1.15 Billion Upfront and $650 Million in Milestones
May 22, 2024, 11:39 AM
Biogen Inc. (Nasdaq: $BIIB) announced on Wednesday that it has agreed to acquire privately held Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in potential milestone payments. The acquisition aims to bolster Biogen's late-stage pipeline and expand its immunology portfolio. HI-Bio is a clinical-stage biotechnology company focused on targeted therapies, including Felzartamab, a Phase 3 CD38 antibody for immunosuppression and other immune-related diseases.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Increase by more than 5% • 25%
Increase by less than 5% • 25%
Decrease by less than 5% • 25%
Decrease by more than 5% • 25%
Biosimilars launched • 50%
Biosimilars not launched • 50%
Approved • 50%
Not Approved • 50%
Q3 2024 • 25%
Q4 2024 • 25%
Later than Q4 2024 • 25%
Not completed • 25%
